The following is a summary of the Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Vivos Therapeutics reported notable Q2 2024 total revenue of $4.1 million, marking a 19% increase sequentially and year-over-year.

• Gross profit for Q2 2024 was $2.7 million with a gross margin of 65%, showing an improvement from 62% in the comparable period in 2023.

• Net loss significantly decreased by 65% to $1.9 million in Q2 2024 compared to the same period last year.

Business Progress:

• Vivos Therapeutics has seen an increased enrollment in its VIP program and an expansion in strategic alliances, including a notable collaboration with a multicenter sleep clinic operation in Colorado.

• The company has improved cost structure and significantly reduced its cash burn, continuing efforts to achieve cash flow positive operations.

• Recent FDA clearance to treat severe OSA using their oral appliances has potentially broadened their market.

Opportunities:

• The strategic alliance with multicenter sleep clinics and the ability to address a broader range of OSA patients with FDA-approved treatment options positions Vivos for a potentially substantial increase in patient referrals and revenue.

Risks:

• The success of new strategic alliances and the ongoing restructure pose execution risks, and the need to balance cost-cutting while scaling operations could impact operational stability.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.